Enzolytics Inc (ENZC)

[falon]

Focus on what we KNOW!


Follow the science....

“It will take longer than you expect — don’t give up.” Charles Cotropia Jun 13, 2019

Cell line is a general term that applies to a defined population of cells that can be maintained in culture for an extended period of time, retaining stability of certain phenotypes and functions. Cell lines are usually clonal, meaning that the entire population originated from a single common ancestor cell.

Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies

NEWS PROVIDED BY Samsung Biologics 07 Oct, 2021, 08:00 ET
https://www.prnewswire.com/news-releases/enzolytics-inc-and-samsung-biologics-announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2-monoclonal-antibody-therapies-301394969.html

Under the terms of the agreement, Samsung Biologics will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2. In addition, there will be continuing discussions for other Monoclonal Antibodies being developed by Enzolytics.

Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology


https://www.stocktitan.net/news/ENZC/enzolytics-inc-announces-program-for-creation-of-multiple-monoclonal-lvnet0g89p2f.html November 8, 2021

Enzolytics, Inc. announces a collaboration with Abveris, a division of Twist Bioscience Corporation, to discover fully human monoclonal antibodies against multiple viruses. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services.

The Company's defined protocol includes:

Application of computer analysis (Artificial Intelligence - A.I.) to curate (analyze) the amino acid sequences of targeted viruses to identify the conserved, immutable, and neutralizable target sites (epitopes) on targeted viruses. Enzolytics has accomplished this goal for HIV, the Coronavirus, HTLV-1, as well as for H10N3, Influenza A, and B, H1N1 influenza, Respiratory syncytial virus (RSV), Ebola, Small-Pox, Tetanus, Diphtheria, Rabies, Herpes zoster, Varicella zoster, Anthrax, Elephant endotheliotropic herpesviruses, Feline Leukemia Virus, Equine Infectious Anemia Virus, Feline Immunodeficiency virus, Small Ruminant Lentivirus, and Koala retrovirus.
The new protocol includes implementing A.I. analysis of existing viruses (or mutants thereof) and on any new virus immediately upon its emergence anywhere in the world.
The A.I. analysis identifies the conserved, immutable, and neutralizable target sites on the subject virus. It provides for the production of multiple monoclonal antibodies, each targeting an immutable epitope for administering combination therapy.
Creation of cell lines to produce monoclonal antibodies targeting each identified conserved virus site (epitope). In this step, multiple broadly neutralizing antibodies are being produced targeting multiple conserved, immutable epitopes on the targeted virus.
The Company utilizes both the Hybridoma Technology and the Phage Display for producing Monoclonal Antibodies for veterinary use.

The monoclonal antibodies for veterinary use at Enzolytics are being created in three phases.

Phase 1
Feline Immunodeficiency virus
Feline Leukemia virus
Equine Infectious Anemia virus
Small Ruminant Lentivirus
SARS-CoV-2 for Wild Animals

Phase 2
Koala retrovirus
Elephant Endotheliotropic Herpesvirus
Camel Pox
Avian Flu
Swine flu
Falcon Herpesvirus

Phase 3
Striped dolphin morbillivirus
Phocine distemper virus

The Company is actively exploring proposals for collaborations and partnerships with U.S. and foreign veterinary companies for their monoclonal antibodies for veterinary use.


Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective Therapies for Treating HIV


https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/12132162/enzolytics-recognizes-world-aids-day-and-highlights-the-companys-focus-on-producing-effective-therapies-for-treating-hiv/ Dec 1, 2022

HIV THERAPEUTICS
Addressing the HIV pandemic, the Company has two expectedly complementary therapeutics directed to the effective treatment of HIV. One therapeutic, ITV-1, a patented antiviral peptide that has been clinically tested, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. This therapeutic has been shown to strengthen the immune system and has been tested in HIV patients in clinical trials with significant beneficial results. [https://enzolytics.com/proprietary-therapeutics/]. Currently, the Company is advancing this anti-HIV therapeutic for approval under the European Medicines Agency (EMA) for use in European Union countries.

The Company also is focused on deploying this tested therapeutic in African countries, where the HIV pandemic is severe. Upon completion of final Toxicity Studies of ITV-1, the Company plans to be able to make ITV-1 available in the countries in Africa, including Rwanda, the Democratic Republic of Congo, Angola, Kenya, and South Africa. The Company sees this as significant for individuals in Africa recognizing that out of the 38.4 Million HIV-positive people worldwide, 69% live in sub-Saharan Africa. There are roughly 23.8 Million infected persons in all of Africa. 40% of those infected with HIV in Africa do not have any access to any treatment for the virus. In addition, 91% of the world's HIV-positive children live in Africa.

The second therapeutic for treating HIV, the Company's anti-HIV monoclonal antibodies, are also in development. The Company's primary anti-HIV antibody has been produced from the parent antibody in the recombinant form (a form necessary for patient treatment) by Samsung Biologics. Samsung Biologics will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for Anti-HIV Monoclonal Antibody Therapy for the treatment of HIV. The Company notes that this anti-HIV mAb targets an immutable site on the HIV virus that has existed unchanged over 30 years of analysis of the virus. This means that the target will not mutate rendering the antibody ineffective.

SARS-CoV-2 THERAPEUTICS
Addressing the COVID-19 pandemic, the Company is producing monoclonal antibodies targeting conserved sites on the SARS-CoV-2 virus identified using Artificial Intelligence. The conserved targeted conserved sites are found in all variants of concern - including the COVID-19 Omicron variant. Thus, the monoclonal antibodies being produced by the Company, due to the conserved nature of the targeted epitopes, are expected to be effective against current and future variants of the COVID-19 virus.

The Company is using multiple processes to accelerate the production of these monoclonal antibodies. As acknowledged by experts in the field, numerous monoclonal antibodies are needed for effective therapy. By using accelerated technology systems in collaboration with Abveris, a division of Twist Bioscience Corporation, desired antibodies may be produced in shorter time frames. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. In addition, the Company has a strong working relationship with Samsung Biologics, which provides end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for produced antibodies.

Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.


https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/18116704/enzolytics-inc-reports-amendment-to-non-binding-term-sheet-with-the-special-purpose-acquisition-company-sagaliam-acquisition-corp/ June 29, 2023

Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, and Sagaliam Acquisition Corp. (NASDAQ:SAGA) ("Sagaliam") (together the "Parties") announced today they have agreed to an amendment to the executed non-binding term sheet for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), operating subsidiaries of the Company, amending the combined purchase price to $450,000,000.00. In addition, the Parties have agreed to a Make Whole calculation six months after close to ensure the value to be received by ENZC. The Parties will now focus on completing the business combination agreement as soon as possible.

Sagaliam expects to raise additional capital through private investment in public equities ("PIPE"). The anticipated capital raise from the PIPE is expected to be primarily used by VIRO to pay transaction-related expenses and fund the clinical trials of it anti-HIV therapeutic ITV-1, complete the African Project and advance marketing of IPF Immune™. The funds are to be used by BGEN to complete the production of and test species-specific monoclonal antibodies (mAbs) for treating COVID-19, HIV, and Feline Leukemia. The funding will significantly enhance BGEN's drug discovery capabilities using its proprietary, cutting-edge Artificial Intelligence (AI) technology and enlarge its IP portfolio while also expanding the AI platform's capabilities to advance health care from that based on reactive disease care to P4 medicine, namely care that is predictive, preventive, personalized and participatory.

EXTRA EXTRA READ ALL ABOUT mAbs are coming from SAGA Scientific Holdings Corp.

In my opinion ENZC is ready for clinical trials for at one if not more of the mAbs.

The only thing holding them up is M O N E Y.